| 000 | 01869 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517055210.0 | ||
| 264 | 0 | _c20160613 | |
| 008 | 201606s 0 0 eng d | ||
| 022 | _a1474-4457 | ||
| 024 | 7 |
_a10.1016/S1473-3099(15)00320-5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPhyo, Aung Pyae | |
| 245 | 0 | 0 |
_aAntimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. _h[electronic resource] |
| 260 |
_bThe Lancet. Infectious diseases _cJan 2016 |
||
| 300 |
_a61-69 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdamantane _xadministration & dosage |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntimalarials _xadministration & dosage |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMalaria, Falciparum _xdrug therapy |
| 650 | 0 | 4 |
_aMalaria, Vivax _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPeroxides _xadministration & dosage |
| 650 | 0 | 4 |
_aThailand _xepidemiology |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aJittamala, Podjanee | |
| 700 | 1 | _aNosten, François H | |
| 700 | 1 | _aPukrittayakamee, Sasithon | |
| 700 | 1 | _aImwong, Mallika | |
| 700 | 1 | _aWhite, Nicholas J | |
| 700 | 1 | _aDuparc, Stephan | |
| 700 | 1 | _aMacintyre, Fiona | |
| 700 | 1 | _aBaker, Mark | |
| 700 | 1 | _aMöhrle, Jörg J | |
| 773 | 0 |
_tThe Lancet. Infectious diseases _gvol. 16 _gno. 1 _gp. 61-69 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S1473-3099(15)00320-5 _zAvailable from publisher's website |
| 999 |
_c25335836 _d25335836 |
||